CYTOKINETICS Business Summary

Cytokinetics Inc. (CYTK) is a commercial-stage biopharmaceutical company that generates revenue through the global sale of its proprietary muscle-directed therapies, collaboration milestones, and strategic licensing agreements. The company’s primary business segments are focused on the discovery and development of first-in-class muscle activators and inhibitors for cardiovascular and neuromuscular diseases. Its flagship product, MYQORZO (aficamten), a cardiac myosin inhibitor, received FDA and European Commission approval in late 2025 for obstructive hypertrophic cardiomyopathy (oHCM), transitioning the firm into a high-growth commercial entity. Cytokinetics competes directly with Bristol Myers Squibb (market-leading Camzyos), Solid Biosciences, and BioAge Labs, positioning itself as a specialized leader in muscle biology with a target of capturing over 50% of the new patient share in the cardiac myosin inhibitor market by the end of 2026. The company was founded in 1997 by a distinguished group of scientists from Stanford, UCSF, and UCSD, including James Spudich, Ronald Vale, James Sabry, and Lawrence S.B. Goldstein. The leadership team is headed by President and CEO Robert I. Blum, who has been with the company since its inception and previously held senior roles at COR Therapeutics. Other key executives include Sung H. Lee (EVP and CFO), Fady Ibraham Malik (EVP of Research and Development), and Andrew Callos (EVP and Chief Commercial Officer). The company is backed by a robust roster of institutional investors, including T. Rowe Price, BlackRock, Vanguard, and Fmr LLC, and is governed by a board featuring prominent industry figures such as Michael Schmertzler, the company’s largest individual insider shareholder.